Ventripoint Appoints Fiona Fitzgerald to the Board of Directors

Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”), (TSXV:VPT); (OTC:VPTDF) is pleased to announce Fiona Fitzgerald has joined the Board of Directors of the Company.

“We are delighted to have Fiona join the Board and look forward to her insights from her decades of experience in sales, marketing and operations,” stated Dr. George Adams Executive-Chairman of Ventripoint.

“I am thrilled with this opportunity. With great AI-enabled technology and a successful round of financing just completed, I see nothing but growth in store for Ventripoint. From my involvement with commercialization activities in Canada I can recognize a winning match of a talented leadership team and and a technology who’s time has arrived,” stated Fiona Fitzgerald.

Fiona Fitzgerald was employed with General Electric Healthcare Corporation (GEHC) in Canada starting in 1995 and transitioned to Cytiva (formerly GEHC Life Sciences) when Danaher Corporation bought the operating company in March 2020. She is an experienced business leader in life sciences with a track record of success in sales, marketing, operations and R&D across three countries: Canada USA and UK/Ireland.

Along with a bachelor’s degree in Applied Biochemical Sciences, she also has a post graduate diploma in Management Sciences. She is also a graduate member of the Chartered Institute of Marketing.

Fiona has participated on various Government of Canada Federal committees including NSERC`s CREATE program and several NSERC Centre of Excellence Evaluation committees. In 2014 she chaired the CREATE Committee. She currently holds board memberships in CellCAN, CATTI, CIMTEC and the Advisory Board for the Centre of Bioengineering and Biotechnology at Waterloo University.

Fiona is actively involved in her community and volunteers with several local organizations.

The Company has awarded Fiona 500,000 options at an exercise price of $.50 with a term of 10 years and a vesting annually over 5 years.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.